Background: Autosomal dominant polycystic kidney disease (ADPKD) causes the development of renal cysts and leads to a decline in renal function. Limited guidance exists in clinical practice on the use of tolvaptan. A decision algorithm from the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Working Groups of Inherited Kidney Disorders and European Renal Best Practice (WGIKD/ERBP) has been proposed to identify candidates for tolvaptan treatment; however, this algorithm has not been assessed in clinical practice. Methods: Eighteen-month cross-sectional, unicenter, observational study assessing 305 consecutive ADPKD patients. The ERA-EDTA WGIKD/ERBP algorithm with a stepwise approach was used to assess rapid progression (RP). Subsequently, expanded criteria based on the REPRISE trial were applied to evaluate the ­impact of extended age (≤55 years) and estimated glomerular filtration rate (eGFR; ≥25 mL/min/1.73 m2). Results: Historical eGFR decline, indicative of RP, was fulfilled in 26% of 73 patients who were candidates for RP assessment, mostly aged 31–55 years. Further tests including ultrasound and MRI measurements of kidney volume plus genetic testing enabled the evaluation of the remaining patients. Overall, 15.7% of patients met the criteria for rapid or likely RP using the algorithm, and the percentage increased to 27% when extending age and eGFR. Conclusions: The ERA-EDTA WGIKD/ERBP algorithm provides a valuable means of identifying in routine clinical practice patients who may be eligible for treatment with tolvaptan. The impact of a new threshold for age and eGFR may increase the percentage of patients to be treated.

Journal Section:
Original Report: Patient-Oriented, Translational Research
Keywords:
Autosomal dominant polycystic kidney disease, Chronic kidney disease, Rapid progression, Prediction, Magnetic resonance imaging, Ultrasound, Gene, Total kidney volume
1.
Grantham JJ: Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359: 1477–1485.
2.
Spithoven EM, Kramer A, Meijer E, et al: Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival – an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant 2014; 29(suppl 4): iv15–iv25.
3.
The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. The European Polycystic Kidney Disease Consortium. Cell 1994; 77: 881–894.
4.
Mochizuki T, Wu G, Hayashi T, et al: PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 1996; 272: 1339–1342.
5.
Torra R, Badenas C, Darnell A, et al: Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2. J Am Soc Nephrol 1996; 7: 2142–2151.
6.
Porath B, Gainullin VG, Cornec-Le Gall E, et al: Mutations in GANAB, encoding the glucosidase IIα subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet 2016; 98: 1193–1207.
7.
Hateboer N, v Dijk MA, Bogdanova N, et al: Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999; 353: 103–107.
8.
Cornec-Le Gall E, Audrézet MP, Chen JM, et al: Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 2013; 24: 1006–1013.
9.
Torra R, Darnell A, Estivill X, Botey A, Revert L: Interfamilial and intrafamilial variability of clinical expression in ADPKD. Contrib Nephrol 1995; 115: 97–101.
10.
European Medicines Agency. Assessment Report: Jinarc. Procedure No. EMEA/H/C/002788/ 0000. EMA/154879/2015. London, England: European Medicines Agency; 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002788/WC500187923.pdf.
11.
Torres VE, Chapman AB, Devuyst O, et al: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407–2418.
12.
Food and Drug Admistration: NDA approval 2018. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/204441Orig1s000ltr.pdf (accessed June 13, 2017).
13.
Gansevoort RT, Arici M, Benzing T, et al: Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant 2016; 31: 337–348.
14.
Torres VE, Chapman AB, Devuyst O, et al: Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 2017; 377: 1930–1942.
15.
Perrone RD, Mouksassi MS, Romero K, et al: Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int Rep 2017; 2: 442–450.
16.
Pei Y, Obaji J, Dupuis A, et al: Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009; 20: 205–212.
17.
Irazabal MV, Rangel LJ, Bergstralh EJ, et al: Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 2015; 26: 160–172.
18.
Cornec-Le Gall E, Audrézet MP, Rousseau A, et al: The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2016; 27: 942–951.
19.
Levey AS, Stevens LA, Schmid CH, et al: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–612.
20.
Trujillano D, Bullich G, Ossowski S, et al: Diagnosis of autosomal dominant polycystic kidney disease using efficient PKD1 and PKD2 targeted next-generation sequencing. Mol Genet Genomic Med 2014; 2: 412–421.
21.
Grantham JJ, Torres VE, Chapman AB, et al: Volume progression in polycystic kidney disease. N Engl J Med 2006; 354: 2122–2130.
22.
Bhutani H, Smith V, Rahbari-Oskoui F, et al: A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int 2015; 88: 146–151.
© 2018 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2018
You do not currently have access to this content.